Evidence-based approaches for the treatment of opioid use disorder include the use of opioid medications (methadone, buprenorphine, or naltrexone), collectively referred to as medication-assisted therapy. Patients receiving medication-assisted therapy may present in the acute care setting with pain, often related to planned surgical procedures to treat health issues that were not addressed before entering treatment. Because these medications act on the same receptors as do analgesic opioids—and, in the cases of methadone and buprenorphine, have analgesic properties — managing acute pain in these patients can be challenging. Principles of effective pain management for these patients include continuing the usual medication-assisted therapy dose; using nonpharmacological and nonopioid pain management strategies as possible and immediate-release opioids, titrating to effect and monitoring for toxicity; anticipating tolerance and hyperalgesia; and establishing a collaborative treatment relationship with the medication-assisted therapy provider. Providing effective pain treatment supports ongoing recovery in patients with opioid use disorder.
Skip Nav Destination
Article navigation
Winter 2019
Symposium: Pain Management Challenges in Acute and Critically Ill Patients|
December 15 2019
Acute Pain Management for Patients Receiving Medication-Assisted Therapy
Peggy Compton, PhD, RN
Peggy Compton, PhD, RN
Peggy Compton is Associate Professor, School of Nursing, University of Pennsylvania, 418 Curie Blvd, Room 402, Philadelphia, PA 19104 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2019) 30 (4): 335–342.
Citation
Peggy Compton; Acute Pain Management for Patients Receiving Medication-Assisted Therapy. AACN Adv Crit Care 15 December 2019; 30 (4): 335–342. doi: https://doi.org/10.4037/aacnacc2019328
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access